Pediatrix Medical Group, Inc. (NYSE:MD) Stake Decreased by Aigen Investment Management LP

Aigen Investment Management LP lessened its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,172 shares of the company’s stock after selling 1,550 shares during the period. Aigen Investment Management LP’s holdings in Pediatrix Medical Group were worth $164,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in MD. nVerses Capital LLC bought a new stake in Pediatrix Medical Group during the second quarter worth approximately $31,000. Innealta Capital LLC bought a new stake in Pediatrix Medical Group during the second quarter worth approximately $33,000. Nisa Investment Advisors LLC raised its holdings in Pediatrix Medical Group by 47.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after purchasing an additional 1,524 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in shares of Pediatrix Medical Group in the second quarter valued at $72,000. Finally, CWM LLC increased its holdings in shares of Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock valued at $74,000 after buying an additional 3,681 shares in the last quarter. Institutional investors own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on MD. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. UBS Group upped their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Jefferies Financial Group upped their price target on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Mizuho upped their price target on Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Finally, StockNews.com raised Pediatrix Medical Group from a “hold” rating to a “buy” rating in a report on Wednesday, November 13th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Pediatrix Medical Group currently has an average rating of “Hold” and an average price target of $16.10.

Insider Activity

In other news, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now owns 30,805 shares of the company’s stock, valued at $343,783.80. This represents a 18.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 53,808 shares of company stock worth $751,277 in the last ninety days. Corporate insiders own 2.00% of the company’s stock.

Pediatrix Medical Group Trading Down 4.1 %

NYSE MD opened at $14.15 on Monday. The firm’s 50 day moving average price is $12.53 and its two-hundred day moving average price is $9.86. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. Pediatrix Medical Group, Inc. has a twelve month low of $6.62 and a twelve month high of $16.41. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -4.62, a PEG ratio of 2.03 and a beta of 1.55.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the previous year, the company posted $0.29 EPS. Pediatrix Medical Group’s revenue was up .9% on a year-over-year basis. Equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.25 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.